Abstract
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10 , 10 , or 1 μM) decreases nerve growth factor (NGF) secretion measured by enzymelinked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Keywords: Gastrin-releasing peptide receptor, RC-3095, nerve growth factor, colon cancer
Protein & Peptide Letters
Title: Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist
Volume: 16 Issue: 6
Author(s): Caroline Brunetto de Farias, Laura Stertz, Rodrigo Cruz Lima, Flavio Kapczinski, Gilberto Schwartsmann and Rafael Roesler
Affiliation:
Keywords: Gastrin-releasing peptide receptor, RC-3095, nerve growth factor, colon cancer
Abstract: The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10 , 10 , or 1 μM) decreases nerve growth factor (NGF) secretion measured by enzymelinked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Export Options
About this article
Cite this article as:
de Farias Brunetto Caroline, Stertz Laura, Lima Cruz Rodrigo, Kapczinski Flavio, Schwartsmann Gilberto and Roesler Rafael, Reduced NGF Secretion by HT-29 Human Colon Cancer Cells Treated with a GRPR Antagonist, Protein & Peptide Letters 2009; 16 (6) . https://dx.doi.org/10.2174/092986609788490177
DOI https://dx.doi.org/10.2174/092986609788490177 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
G and C Iterons and Strings in MicroRNAs Should be Important in Regulation of mRNAs<sup>†</sup>
MicroRNA The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets MicroRNAs as Potential Therapeutic Agents in the Treatment of Myocardial Infarction
Current Vascular Pharmacology Bone Regeneration and Repair
Current Stem Cell Research & Therapy The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Theranostic Radiopharmaceuticals Based on Gold Nanoparticles Labeled with <sup>177</sup>Lu and Conjugated to Peptides
Current Radiopharmaceuticals Glucose-6-Phosphate Dehydrogenase Deficiency: Disadvantages and Possible Benefits
Cardiovascular & Hematological Disorders-Drug Targets On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Fluorescence-Guided Malignant Glioma Resections
Current Drug Discovery Technologies Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile
Current Pharmaceutical Design Studies on Non-synonymous Polymorphisms Altering Human DNA Topoisomerase II-Alpha Interaction with Amsacrine and Mitoxantrone: An <i>In Silico</i> Approach
Current Cancer Drug Targets Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Anti-cancer Drug Discovery: Update and Comparisons in Yeast, Drosophila, and Zebrafish
Current Molecular Pharmacology Colchicine in Neurosurgery
Current Pharmaceutical Design Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry